Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imraldi

- PMLiVE

FDA approves AbbVie’s Duopa in advanced Parkinson’s

Drug is administered into the stomach via a tube

- PMLiVE

EC clears AbbVie’s oral hepatitis C regimen

Viekirax and Exviera offer competition to Gilead’s Sovaldi

- PMLiVE

Sovaldi dropped by Express Scripts in favour of Viekira Pak

Pharmacy benefits organisation ramps up US pricing pressure on Gilead

- PMLiVE

AbbVie wins key approval for hep C pill Viekira Pak

Prices all-oral treatment fractionally lower than rivals from Gilead

- PMLiVE

NICE backs three ulcerative colitis treatments

Remicade, Simponi and Humira recommended for NHS reimbursement

- PMLiVE

First biosimilar Humira launches in India

AbbVie to face competition for world’s biggest-selling drug

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

EMA recommends two AbbVie treatments for hepatitis C

Exviera and Viekirax backed for use in Europe

EU flag

EU watchdog raps EMA for redacted AbbVie data

Issues over the redaction of clinical study reports

- PMLiVE

AbbVie takes home company of the year at PMEA 2014

Firm is rewarded for its patient-focus

- PMLiVE

AbbVie is not looking at another big acquisition, says CEO

Unlikely to consider another deal on the scale of failed Shire merger

- PMLiVE

AbbVie and Shire bring merger plans to a close

Blames tax changes in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links